Back to Article List

Biotechnology in China – regulation, investment, and delayed commercialization


May 16, 2022

China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles – some more than a decade ago – commercialization has not been approved. The regulatory regime for GMOs in China is relatively less well understood than that of the US or the EU. This paper provides a systematic overview of China’s regulatory regime, R&D investment and delayed commercialization decisions on biotechnology over the last 40 years and draws some conclusions regarding the likelihood of the commercialization for major GM crops in the future.

For further information, click on the:



Related Articles
See All News
Subscribe to our newsletter

The best industry insight in your mailbox